Case Type: Mergers & Acquisitions

MeridianLink, Inc. (NYSE: MLNK) related to its sale to affiliates of Centerbridge Partners, L.P. for $20.00 per share in cash.

International Money Express, Inc. (NASDAQ: IMXI) related to its sale to The Western Union Company. Under the terms of the proposed transaction, International shareholders will receive $16.00 in cash per International share.

Monroe Capital Corporation (NASDAQ: MRCC) related to its sale to Horizon Technology Finance Corporation. Under the terms of the proposed transaction, Monroe shares will be converted into the right to receive Horizon shares subject to an Exchange Ratio.

Aris Water Solutions, Inc. (NYSE: ARIS) related to its sale to Western Midstream Partners LP. Under the terms of the proposed transaction, Aris shareholders will receive either 0.625 common units of Western for each Aris share or $25.00 per share in cash.

American Woodmark Corporation (NASDAQ: AMWD) related to its sale to MasterBrand, Inc. Under the terms of the proposed transaction, each share of American common stock will be exchanged for 5.150 shares of MasterBrand common stock.

Steelcase Inc. (NYSE: SCS) related to its sale to HNI Corporation for $7.20 per share in cash and 0.2192 shares of HNI common stock for each share of Steelcase.

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) related to its sale to SERB Pharmaceuticals. Under the terms of the proposed transaction, Y-mAbs shareholders will receive $8.60 in cash per share.

STAAR Surgical Company (NASDAQ: STAA) related to its sale to Alcon Research LLC. Under the terms of the proposed transaction, STAAR shareholders will receive $28.00 in cash per share.

LAVA Therapeutics N.V. (NASDAQ: LVTX) related to its sale to XOMA Royalty Corporation. Under the terms of the proposed transaction, XOMA Royalty will acquire LAVA for $1.16 in cash per share, plus up to $0.08 per share and a non-transferable contingent value right per share representing the right to receive 75% of the net proceeds … Read more

HilleVax, Inc. (NASDAQ: HLVX) related to its sale to XOMA Royalty Corporation. Under the terms of the proposed transaction, HilleVax stockholders will receive $1.95 in cash per share, plus one non-transferable contingent value right, representing the right to receive additional payments under certain post-closing financial conditions.